Biology Atlas

Map / People

person · intermediate · partly written

Yana Pikman, MD

Pediatric hematologist-oncologist at Dana-Farber Cancer Institute who leads the Pikman Lab on pediatric leukemia.

Also called: Yana Pikman

Position and training as printed

Dana-Farber prints her as Assistant Professor of Pediatrics at Harvard Medical School and Co-Director of the Hematologic Malignancy Program, with an MD from Harvard Medical School, residency in the Boston Combined Residency Program and a pediatric hematology and oncology fellowship at Boston Children's and Dana-Farber. A conflicting page calling her Associate Professor was not accepted over the institute page. 1

Reported, not yet replicated

What her record rests on more

First author of the 2016 MTHFD2 paper in AML, the 2021 LEAP matched-therapy study and the 2022 SHMT1/2 paper in T-ALL; middle or late author on the 2025 to 2026 papers visible in the record. The LEAP study reports feasibility, not response: 17 patients received the matched drug and the paper reports no response rate. 234

Reported, not yet replicated

Public role

Assistant Professor of Pediatrics, Harvard Medical School; Co-Director, Hematologic Malignancy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Affiliation

Dana-Farber Cancer Institute; Harvard Medical School

Works on

Matched targeted therapy for relapsed and high-risk pediatric leukemia and one-carbon metabolism as a leukemia dependency. 15

Reported, not yet replicated

Profile URL

www.dana-farber.org/find-a-doctor/yana-pikman

Still open here

Linked from

Sources

  1. Yana Pikman, MD (Dana-Farber physician profile). (2026). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
  2. Pikman Y, et al. Targeting MTHFD2 in acute myeloid leukemia (J Exp Med 2016). (2016). paper; opened 2026-11-17 all records citing this
  3. Pikman Y, et al. Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: a report from the LEAP Consortium (Cancer Discovery 2021). (2021). paper; opened 2026-11-17 all records citing this
  4. Pikman Y, et al. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy (Leukemia 2022). (2022). paper; opened 2026-11-17 all records citing this
  5. Pikman Lab: research (Dana-Farber). (2026). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (3)

This record has been changed 3 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
partly written
Last updated
2026-11-19
Record
content/people/yana-pikman.json